請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66444
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 謝豐舟,何奕倫 | |
dc.contributor.author | Yen-Hung Lin | en |
dc.contributor.author | 林彥宏 | zh_TW |
dc.date.accessioned | 2021-06-17T00:36:08Z | - |
dc.date.available | 2015-03-02 | |
dc.date.copyright | 2012-03-02 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2012-02-03 | |
dc.identifier.citation | Aronson D, Mittleman MA, Burger AJ, Measures of heart period variability as predictors of mortality in hospitalized patients with decompensated congestive heart failure. Am J Cardiol 2004;93:59-63.
Ayus JC, Go AS, Valderrabano F, Verde E, de Vinuesa SG, Achinger SG, Lorenzo V, Arieff AI, Luno J, Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL. Kidney Int 2005;68:788-95. Bernini G, Galetta F, Franzoni F, Bardini M, Taurino C, Bernardini M, Ghiadoni L, Bernini M, Santoro G, Salvetti A, Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism. J Hypertens 2008;26:2399-405. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG, Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003;63:1791-800. Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, Lorenz R, Allolio B, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M, Endres S, Quinkler M, Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab 2009;94:1125-30. Brilla CG, Matsubara LS, Weber KT, Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993;25:563-75. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT, Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990;67:1355-64. Brilla CG, Weber KT, Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992;26:671-7. Brilla CG, Zhou G, Matsubara L, Weber KT, Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994;26:809-20. Callera GE, Touyz RM, Tostes RC, Yogi A, He Y, Malkinson S, Schiffrin EL, Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 2005;45:773-9. Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, Sechi LA, Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007;50:911-8. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA, Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008;168:80-5. Caulfield JB, Borg TK, The collagen network of the heart. Lab Invest 1979;40:364-72. Chang HW, Chu TS, Huang HY, Chueh SC, Wu VC, Chen YM, Hsieh BS, Wu KD, Down-regulation of D2 dopamine receptor and increased protein kinase Cmu phosphorylation in aldosterone-producing adenoma play roles in aldosterone overproduction. J Clin Endocrinol Metab 2007;92:1863-70. Chang HW, Wu VC, Huang CY, Huang HY, Chen YM, Chu TS, Wu KD, Hsieh BS, D4 dopamine receptor enhances angiotensin II-stimulated aldosterone secretion through PKC-epsilon and calcium signaling. Am J Physiol Endocrinol Metab 2008;294:E622-9. Cicoira M, Rossi A, Bonapace S, Zanolla L, Golia G, Franceschini L, Caruso B, Marino PN, Zardini P, Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J Card Fail 2004;10:403-11. Coca SG, Perazella MA, Buller GK, The cardiovascular implications of hypokalemia. Am J Kidney Dis 2005;45:233-47. Corry DB, Tuck ML, The effect of aldosterone on glucose metabolism. Curr Hypertens Rep 2003;5:106-9. De Boeck BW, Cramer MJ, Oh JK, van der Aa RP, Jaarsma W, Spectral pulsed tissue Doppler imaging in diastole: a tool to increase our insight in and assessment of diastolic relaxation of the left ventricle. Am Heart J 2003;146:411-9. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ, Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011;43:60-8. de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ, Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009;11:811-7. de Kloet ER, Van Acker SA, Sibug RM, Oitzl MS, Meijer OC, Rahmouni K, de Jong W, Brain mineralocorticoid receptors and centrally regulated functions. Kidney Int 2000;57:1329-36. De Rosa M, Galatola M, Quaglietta L, Miele E, De Palma G, Rossi GB, Staiano A, Izzo P, Alu-mediated genomic deletion of the serine/threonine protein kinase 11 (STK11) gene in Peutz-Jeghers syndrome. Gastroenterology 2010;138:2558-60. Dekker JM, Schouten EG, Klootwijk P, Pool J, Swenne CA, Kromhout D, Heart rate variability from short electrocardiographic recordings predicts mortality from all causes in middle-aged and elderly men. The Zutphen Study. Am J Epidemiol 1997;145:899-908. Di Bello V, Giorgi D, Talini E, Dell' Omo G, Palagi C, Romano MF, Pedrinelli R, Mariani M, Incremental value of ultrasonic tissue characterization (backscatter) in the evaluation of left ventricular myocardial structure and mechanics in essential arterial hypertension. Circulation 2003;107:74-80. Di Bello V, Giorgi D, Viacava P, Enrica T, Nardi C, Palagi C, Grazia Delle Donne M, Verunelli F, Mariani MA, Grandjean J, Dell'Anna R, Di Cori A, Zucchelli G, Romano MF, Mariani M, Severe aortic stenosis and myocardial function: diagnostic and prognostic usefulness of ultrasonic integrated backscatter analysis. Circulation 2004;110:849-55. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, De Caterina R, Dean V, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-442. Diez J, Panizo A, Gil MJ, Monreal I, Hernandez M, Pardo Mindan J, Serum markers of collagen type I metabolism in spontaneously hypertensive rats: relation to myocardial fibrosis. Circulation 1996;93:1026-32. Dooley R, Harvey BJ, Thomas W, Non-genomic actions of aldosterone: From receptors and signals to membrane targets. Mol Cell Endocrinol 2011. Ellis D, Banner B, Janosky JE, Feig PU, Potassium supplementation attenuates experimental hypertensive renal injury. J Am Soc Nephrol 1992;2:1529-37. Ezekowitz JA, McAlister FA, Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 2009;30:469-77. Farquharson CA, Struthers AD, Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594-7. Fitzovich DE, Hamaguchi M, Tull WB, Young DB, Chronic hypokalemia and the left ventricular responses to epinephrine and preload. J Am Coll Cardiol 1991;18:1105-11. Fletcher J, Buch AN, Routledge HC, Chowdhary S, Coote JH, Townend JN, Acute aldosterone antagonism improves cardiac vagal control in humans. J Am Coll Cardiol 2004;43:1270-5. Francis J, Beltz T, Johnson AK, Felder RB, Mineralocorticoids act centrally to regulate blood-borne tumor necrosis factor-alpha in normal rats. Am J Physiol Regul Integr Comp Physiol 2003;285:R1402-9. Funder J, Myles K, Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology 1996;137:5264-8. Funder JW, Aldosterone and mineralocorticoid receptors in the cardiovascular system. Prog Cardiovasc Dis 2010;52:393-400. Galetta F, Bernini G, Franzoni F, Bacca A, Fivizzani I, Tocchini L, Bernini M, Fallahi P, Antonelli A, Santoro G, Cardiac Remodeling in Patients with Primary Aldosteronism. J Endocrinol Invest 2009. George J, Patal S, Wexler D, Roth A, Sheps D, Keren G, Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 2005;150:484-7. Gomez-Sanchez EP, Intracerebroventricular infusion of aldosterone induces hypertension in rats. Endocrinology 1986;118:819-23. Gonzalez A, Lopez B, Ravassa S, Beaumont J, Arias T, Hermida N, Zudaire A, Diez J, Biochemical markers of myocardial remodelling in hypertensive heart disease. Cardiovasc Res 2009;81:509-18. Graham HK, Horn M, Trafford AW, Extracellular matrix profiles in the progression to heart failure. European Young Physiologists Symposium Keynote Lecture-Bratislava 2007. Acta Physiol (Oxf) 2008;194:3-21. Hall CS, Scott MJ, Lanza GM, Miller JG, Wickline SA, The extracellular matrix is an important source of ultrasound backscatter from myocardium. J Acoust Soc Am 2000;107:612-9. Heeneman S, Cleutjens JP, Faber BC, Creemers EE, van Suylen RJ, Lutgens E, Cleutjens KB, Daemen MJ, The dynamic extracellular matrix: intervention strategies during heart failure and atherosclerosis. J Pathol 2003;200:516-25. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, Liu FT, Hughes J, Sethi T, Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008;172:288-98. Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, Haslett C, Simpson KJ, Sethi T, Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A 2006;103:5060-5. Herrada AA, Campino C, Amador CA, Michea LF, Fardella CE, Kalergis AM, Aldosterone as a modulator of immunity: implications in the organ damage. J Hypertens 2011;29:1684-92. Ho YL, Chen CL, Hsu RB, Lin LC, Yen RF, Lee CM, Chen MF, Huang PJ, Assessment of the myocardial changes in heart transplant recipients without evident acute myocardial rejection by integrated backscatter: comparison with simultaneous dobutamine stress echocardiography and (201)thallium spect. Ultrasound Med Biol 2001;27:171-9. Ho YL, Lin YH, Lee CM, Hsu RB, Ting HT, Chou NK, Chao CL, Wang SS, Hsu HC, Chen MF, Prognostic significance of adipocytokines and extracellular matrix activity in heart failure patients with high B-type natriuretic peptide. Clin Biochem 2009;42:1407-12. Holaj R, Zelinka T, Wichterle D, Petrak O, Strauch B, Widimsky J, Jr., Increased intima-media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension. J Hypertens 2007;25:1451-7. Holland MR, Wilkenshoff UM, Finch-Johnston AE, Handley SM, Perez JE, Miller JG, Effects of myocardial fiber orientation in echocardiography: quantitative measurements and computer simulation of the regional dependence of backscattered ultrasound in the parasternal short-axis view. J Am Soc Echocardiogr 1998;11:929-37. Horita Y, Inenaga T, Nakahama H, Ishibashi-Ueda H, Kawano Y, Nakamura S, Horio T, Okuda N, Ando M, Takishita S, Cause of residual hypertension after adrenalectomy in patients with primary aldosteronism. Am J Kidney Dis 2001;37:884-9. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:e391-479. Irita J, Okura T, Manabe S, Kurata M, Miyoshi K, Watanabe S, Fukuoka T, Higaki J, Plasma osteopontin levels are higher in patients with primary aldosteronism than in patients with essential hypertension. Am J Hypertens 2006;19:293-7. Kablak-Ziembicka A, Przewlocki T, Pieniazek P, Musialek P, Sokolowski A, Drwila R, Sadowski J, Zmudka K, Tracz W, The role of carotid intima-media thickness assessment in cardiovascular risk evaluation in patients with polyvascular atherosclerosis. Atherosclerosis 2010;209:125-30. Kageyama Y, Bravo EL, Hypertensive mechanisms associated with centrally administered aldosterone in dogs. Hypertension 1988;11:750-3. Kleiger RE, Miller JP, Bigger JT, Jr., Moss AJ, Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;59:256-62. Kontak AC, Wang Z, Arbique D, Adams-Huet B, Auchus RJ, Nesbitt SD, Victor RG, Vongpatanasin W, Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism. J Clin Endocrinol Metab 2010;95:4756-61. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH, Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-52. Kozakova M, Buralli S, Palombo C, Bernini G, Moretti A, Favilla S, Taddei S, Salvetti A, Myocardial ultrasonic backscatter in hypertension: relation to aldosterone and endothelin. Hypertension 2003;41:230-6. Kuo CC, Yang WS, Wu VC, Tsai CW, Wang WJ, Wu KD, Hypokalemic paralysis: the interplay between primary aldosteronism and hyperthyroidism. Eur J Clin Invest 2009;39:738-9. Kuo CC, Yang WS, Wu VC, Tsai CW, Wang WJ, Wu KD, Hypokalemic paralysis: the interplay between primary aldosteronism and hyperthyroidism. Eur J Clin Invest 2009. Lee JK, Lin HH, Tsai CT, Chen JJ, Kuo CC, Lien YC, Lin JW, Huang JW, Hwang SW, Hwang JJ, Tseng CD, Chiang FT, Wu CK, Differential association of proinflammatory cytokines with left ventricular diastolic dysfunction in subjects with and without continuous ambulatory peritoneal dialysis. Nutr Metab Cardiovasc Dis 2011. Lenzen MJ, Scholte op Reimer WJ, Boersma E, Vantrimpont PJ, Follath F, Swedberg K, Cleland J, Komajda M, Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 2004;25:1214-20. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP, Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6. Lin LC, Wu CC, Ho YL, Chen MF, Liau CS, Lee YT, Ultrasonic tissue characterization in predicting residual ischemia and myocardial viability for patients with acute myocardial infarction. Ultrasound Med Biol 1998;24:1107-20. Lin LC, Wu CC, Ho YL, Lin CW, Chen WJ, Chen MF, Liau CS, Lee YT, Ultrasonic tissue characterization for coronary care unit patients with acute myocardial infarction. Ultrasound Med Biol 1998;24:187-96. Lin SL, Castano AP, Nowlin BT, Lupher ML, Jr., Duffield JS, Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J Immunol 2009;183:6733-43. Lin YH, Chiu YW, Shiau YC, Yen RF, Tsai IJ, Ho YL, Huang PJ, The relation between serum level of amioterminal propeptide of type I procollagen and diastolic dysfunction in hypertensive patients without diabetes mellitus: A pilot study. J Hum Hypertens 2006;20:964-7. Lin YH, Ho YL, Wang TD, Liu CP, Kao HL, Chao CL, Chien KL, Hung CS, Wu VC, Tsai IJ, Yen RF, Shiau YC, Chen WJ, The relation of amino-terminal propeptide of type III procollagen and severity of coronary artery disease in patients without myocardial infarction or hibernation. Clin Biochem 2006;39:861-6. Lin YH, Huang KH, Lee JK, Wang SM, Yen RF, Wu VC, Chung SD, Liu KL, Chueh SC, Lin LY, Ho YL, Chen MF, Wu KD, Factors influencing left ventricular mass regression in patients with primary aldosteronism post adrenalectomy. J Renin Angiotensin Aldosterone Syst 2011;12:48-53. Lin YH, Lee HH, Liu KL, Lee JK, Shih SR, Chueh SC, Lin WC, Lin LC, Lin LY, Chung SD, Wu VC, Kuo CC, Ho YL, Chen MF, Wu KD, Reversal of myocardial fibrosis in patients with unilateral hyperaldosteronism receiving adrenalectomy. Surgery 2011;150:526-33. Lin YH, Lin C, Lo MT, Lin HJ, Wu YW, Hsu RB, Chao CL, Hsu HC, Wang PC, Wu VC, Wang SS, Lee CM, Chien KL, Ho YL, Chen MF, Peng CK, The relationship between aminoterminal propeptide of type III procollagen and heart rate variability parameters in heart failure patients: a potential serum marker to evaluate cardiac autonomic control and sudden cardiac death. Clin Chem Lab Med 2010. Lin YH, Lin LY, Wu YW, Chien KL, Lee CM, Hsu RB, Chao CL, Wang SS, Hsein YC, Liao LC, Ho YL, Chen MF, The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 2009;409:96-9. Lin YH, Liu CP, Hsu RB, Lee CM, Wang SS, Kao HL, Chao CL, Shiau YC, Hung CS, Liao LC, Ho YL, Association of amino-terminal propeptide of type III procollagen and acute myocardial rejection in male patients receiving heart transplantation. Clin Chem Lab Med 2007;45:1004-8. Lin YH, Shiau YC, Yen RF, Lin LC, Wu CC, Ho YL, Huang PJ, The relation between myocardial cyclic variation of integrated backscatter and serum concentrations of procollagen propeptides in hypertensive patients. Ultrasound Med Biol 2004;30:885-91. Lin YH, Wang SM, Wu VC, Lee JK, Kuo CC, Yen RF, Liu KL, Huang KH, Chueh SC, Wang WJ, Lin LY, Chien KL, Ho YL, Chen MF, Wu KD, The association of serum potassium level with left ventricular mass in patients with primary aldosteronism. Eur J Clin Invest 2011;41:743-50. Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, van Veldhuisen DJ, Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010;99:323-8. Lopez B, Gonzalez A, Varo N, Laviades C, Querejeta R, Diez J, Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001;38:1222-6. Lopez B, Querejeta R, Varo N, Gonzalez A, Larman M, Martinez Ubago JL, Diez J, Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001;104:286-91. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M, Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007;115:459-67. Luther JM, Gainer JV, Murphey LJ, Yu C, Vaughan DE, Morrow JD, Brown NJ, Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension 2006;48:1050-7. Ma TK, Kam KK, Yan BP, Lam YY, Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol 2010;160:1273-92. Maceira AM, Barba J, Beloqui O, Diez J, Ultrasonic backscatter and diastolic function in hypertensive patients. Hypertension 2002;40:239-43. Maceira AM, Barba J, Varo N, Beloqui O, Diez J, Ultrasonic backscatter and serum marker of cardiac fibrosis in hypertensives. Hypertension 2002;39:923-8. MacFadyen RJ, Barr CS, Struthers AD, Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997;35:30-4. Matsukawa T, Miyamoto T, Does infusion of ANG II increase muscle sympathetic nerve activity in patients with primary aldosteronism? Am J Physiol Regul Integr Comp Physiol 2008;294:R1873-9. Matsumura K, Fujii K, Oniki H, Oka M, Iida M, Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens 2006;19:13-8. Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML, Schalekamp MA, Asmar R, Reneman RS, Hoeks AP, Breteler MM, Witteman JC, Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 2006;113:657-63. Mc AP, Myocardial changes occurring in potassium deficiency. Br Heart J 1955;17:5-14. Melendez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL, Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 2010;56:225-31. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ, Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243-8. Mimbs JW, O'Donnell M, Bauwens D, Miller JW, Sobel BE, The dependence of ultrasonic attenuation and backscatter on collagen content in dog and rabbit hearts. Circ Res 1980;47:49-58. Miyajima E, Yamada Y, Yoshida Y, Matsukawa T, Shionoiri H, Tochikubo O, Ishii M, Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension 1991;17:1057-62. Nishi Y, Sano H, Kawashima T, Okada T, Kuroda T, Kikkawa K, Kawashima S, Tanabe M, Goto T, Matsuzawa Y, Matsumura R, Tomioka H, Liu FT, Shirai K, Role of galectin-3 in human pulmonary fibrosis. Allergol Int 2007;56:57-65. Nishimura RA, Abel MD, Hatle LK, Tajik AJ, Assessment of diastolic function of the heart: background and current applications of Doppler echocardiography. Part II. Clinical studies. Mayo Clin Proc 1989;64:181-204. Nomura K, Toraya S, Horiba N, Ujihara M, Aiba M, Demura H, Plasma aldosterone response to upright posture and angiotensin II infusion in aldosterone-producing adenoma. J Clin Endocrinol Metab 1992;75:323-7. Novitsky YW, Kercher KW, Rosen MJ, Cobb WS, Jyothinagaram S, Heniford BT, Clinical outcomes of laparoscopic adrenalectomy for lateralizing nodular hyperplasia. Surgery 2005;138:1009-16; discussion 16-7. O'Brien PD, O'Brien WD, Jr., Rhyne TL, Warltier DC, Sagar KB, Relation of ultrasonic backscatter and acoustic propagation properties to myofibrillar length and myocardial thickness. Circulation 1995;91:171-5. O'Donnell M, Mimbs JW, Miller JG, Relationship between collagen and ultrasonic backscatter in myocardial tissue. J Acoust Soc Am 1981;69:580-8. Obara T, Ito Y, Okamoto T, Kanaji Y, Yamashita T, Aiba M, Fujimoto Y, Risk factors associated with postoperative persistent hypertension in patients with primary aldosteronism. Surgery 1992;112:987-93. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlof B, Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. Jama 2004;292:2343-9. Okoshi MP, Yan X, Okoshi K, Nakayama M, Schuldt AJ, O'Connell TD, Simpson PC, Lorell BH, Aldosterone directly stimulates cardiac myocyte hypertrophy. J Card Fail 2004;10:511-8. Omura M, Sasano H, Fujiwara T, Yamaguchi K, Nishikawa T, Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selective adrenal venous sampling. Metabolism 2002;51:350-5. Pearson AC, Labovitz AJ, Mrosek D, Williams GA, Kennedy HL, Assessment of diastolic function in normal and hypertrophied hearts: comparison of Doppler echocardiography and M-mode echocardiography. Am Heart J 1987;113:1417-25. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17. Proye CA, Mulliez EA, Carnaille BM, Lecomte-Houcke M, Decoulx M, Wemeau JL, Lefebvre J, Racadot A, Ernst O, Huglo D, Carre A, Essential hypertension: first reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism? Surgery 1998;124:1128-33. Querejeta R, Lopez B, Gonzalez A, Sanchez E, Larman M, Martinez Ubago JL, Diez J, Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 2004;110:1263-8. Querejeta R, Varo N, Lopez B, Larman M, Artinano E, Etayo JC, Martinez Ubago JL, Gutierrez-Stampa M, Emparanza JI, Gil MJ, Monreal I, Mindan JP, Diez J, Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000;101:1729-35. Quintana M, Storck N, Lindblad LE, Lindvall K, Ericson M, Heart rate variability as a means of assessing prognosis after acute myocardial infarction. A 3-year follow-up study. Eur Heart J 1997;18:789-97. Ribstein J, Du Cailar G, Fesler P, Mimran A, Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol 2005;16:1320-5. Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ, Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 2009;54:537-43. Rodriguez L, Garcia M, Ares M, Griffin BP, Nakatani S, Thomas JD, Assessment of mitral annular dynamics during diastole by Doppler tissue imaging: comparison with mitral Doppler inflow in subjects without heart disease and in patients with left ventricular hypertrophy. Am Heart J 1996;131:982-7. Roegel JC, Toussaint M, Ehrhart J, Stephan D, Imbs JL, [Altered heart rate variability but preserved temporal relationship with sleep stages in a patient with primary aldosteronism]. Arch Mal Coeur Vaiss 2001;94:937-40. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F, A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006;48:2293-300. Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, Giorgi D, Scognamiglio R, Mariani M, Pessina AC, Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002;40:23-7. Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C, Pessina AC, Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 1997;95:1471-8. Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, Pessina AC, Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996;27:1039-45. Rossi GP, Seccia TM, Pessina AC, Primary aldosteronism - part I: prevalence, screening, and selection of cases for adrenal vein sampling. J Nephrol 2008;21:447-54. Rundback JH, Sacks D, Kent KC, Cooper C, Jones D, Murphy T, Rosenfield K, White C, Bettmann M, Cortell S, Puschett J, Clair D, Cole P, Guidelines for the reporting of renal artery revascularization in clinical trials. American Heart Association. Circulation 2002;106:1572-85. Sawka AM, Young WF, Thompson GB, Grant CS, Farley DR, Leibson C, van Heerden JA, Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 2001;135:258-61. Shapiro JI, Kennedy DJ, Malhotra D, Xie M, Vetteth S, Hypokalemia potentiates ouabain's effect on calcium cycling and cardiac growth. Cell Mol Biol (Noisy-le-grand) 2006;52:87-91. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, Andre S, Crijns HJ, Gabius HJ, Maessen J, Pinto YM, Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004;110:3121-8. Srivastava TN, Young DB, Impairment of cardiac function by moderate potassium depletion. J Card Fail 1995;1:195-200. Stehr CB, Mellado R, Ocaranza MP, Carvajal CA, Mosso L, Becerra E, Solis M, Garcia L, Lavandero S, Jalil J, Fardella CE, Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients. J Hypertens 2010;28:2120-6. Strauch B, Petrak O, Wichterle D, Zelinka T, Holaj R, Widimsky J, Jr., Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension. Am J Hypertens 2006;19:909-14. Strauch B, Petrak O, Zelinka T, Wichterle D, Holaj R, Kasalicky M, Safarik L, Rosa J, Widimsky J, Jr., Adrenalectomy improves arterial stiffness in primary aldosteronism. Am J Hypertens 2008;21:1086-92. Sun Y, Ramires FJ, Weber KT, Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res 1997;35:138-47. Swynghedauw B, Molecular mechanisms of myocardial remodeling. Physiol Rev 1999;79:215-62. Tanabe A, Naruse M, Naruse K, Hase M, Yoshimoto T, Tanaka M, Seki T, Demura R, Demura H, Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension. Hypertens Res 1997;20:85-90. Tang WH, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD, Klein AL, Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol 2011;108:385-90. Tepper SH, Anderson PA, Mergner WJ, Recovery of heart tissue following focal injury induced by dietary restriction of potassium. Pathol Res Pract 1990;186:265-82. Thomas GD, O'Hagan KP, Zambraski EJ, Chemical sympathectomy alters the development of hypertension in miniature swine. Hypertension 1991;17:357-62. Tobian L, MacNeill D, Johnson MA, Ganguli MC, Iwai J, Potassium protection against lesions of the renal tubules, arteries, and glomeruli and nephron loss in salt-loaded hypertensive Dahl S rats. Hypertension 1984;6:I170-6. Tsioufis C, Tsiachris D, Dimitriadis K, Stougiannos P, Missovoulos P, Kakkavas A, Stefanadis C, Kallikazaros I, Myocardial and aortic stiffening in the early course of primary aldosteronism. Clin Cardiol 2008;31:431-6. Tsuji H, Venditti FJ, Jr., Manders ES, Evans JC, Larson MG, Feldman CL, Levy D, Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation 1994;90:878-83. Verdecchia P, Angeli F, Borgioni C, Gattobigio R, de Simone G, Devereux RB, Porcellati C, Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 2003;16:895-9. Verdecchia P, Schillaci G, Borgioni C, Gattobigio R, Ambrosio G, Porcellati C, Prevalent influence of systolic over pulse pressure on left ventricular mass in essential hypertension. Eur Heart J 2002;23:658-65. Verdecchia P, Schillaci G, Guerrieri M, Gatteschi C, Benemio G, Boldrini F, Porcellati C, Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990;81:528-36. Volpe M, Camargo MJ, Mueller FB, Campbell WG, Jr., Sealey JE, Pecker MS, Sosa RE, Laragh JH, Relation of plasma renin to end organ damage and to protection of K+ feeding in stroke-prone hypertensive rats. Hypertension 1990;15:318-26. Wang GD, Shen LH, Wang L, Li HW, Zhang YC, Chen H, Relationship between integrated backscatter and atrial fibrosis in patients with and without atrial fibrillation who are undergoing coronary bypass surgery. Clin Cardiol 2009;32:E56-61. Wang Q, Domenighetti AA, Pedrazzini T, Burnier M, Potassium supplementation reduces cardiac and renal hypertrophy independent of blood pressure in DOCA/salt mice. Hypertension 2005;46:547-54. Wang W, McClain JM, Zucker IH, Aldosterone reduces baroreceptor discharge in the dog. Hypertension 1992;19:270-7. Watson T, Karthikeyan VJ, Lip GY, Beevers G, Atrial fibrillation in primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2009. Weber KT, Brilla CG, Janicki JS, Reddy HK, Campbell SE, Myocardial fibrosis: role of ven | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66444 | - |
dc.description.abstract | 原發性皮質醛酮症是一個可以治癒的常見高血壓疾病(Wu, Chen 2001)(Wu, Chen 2001)(Wu, Chen 2001)(Wu, Chen 2001)(Wu, Chen 2001),它是由於因腎上腺有腫瘤或不正常增生而分泌過多之皮質醛酮所造成;其盛行率約佔了高血壓病人中百分之五到十。原發性皮質醛酮症最常見有兩種亞型,第一型單側皮質醛酮素瘤及第二型雙側腎上腺增生。
原發性皮質醛酮症較原發性高血壓的患者有更高的心血管疾病的罹病率及心房顫動的發生率,而這現象與血壓影響無關;此外,原發性皮質醛酮症患者較原發性高血壓的患者有較厲害的左心室肥厚、左心室舒張功能異常及心肌纖維化之現象。近來研究顯示皮質醛酮之所以造成心肌纖維化,巨噬細胞所媒介的低密度系統性發炎反應扮演著極為重要的角色,然而其中的媒介物仍不清楚。 在第一部份的研究發現原發性皮質醛酮症患者的血鉀濃度和左心室質量指數呈現著獨立性的負相關;原發性皮質醛酮症患者比原發性高血壓患者有較差的左心室舒張功能,此現象與患者血鉀濃度無關。在第二部份的研究發現腎上腺切除術可顯著改善原發性皮質醛酮症患者的左心室肥大;術前左心室質量指數及手術前後收縮壓差異與左心室質量指數降幅有顯著相關。在第三及第四部份的研究發現單側原發性皮質醛酮症患者較原發性高血壓患者有著較明顯的心臟結構及心肌質地的變化,這個發現支持前人所提到的皮質醛酮有著和血壓無關的導致心肌纖維化效果;單側原發性皮質醛酮症患者在腎上腺切除後,心臟結構及心肌質地均有改善,這暗示著,原發性皮質醛酮症患者的心肌纖維化在腎上腺切除後是可以改善的。第五部份的研究是從細胞研究探討皮質醛酮是否刺激巨噬細胞分泌galectin-3及其作用之機轉,研究發現皮質醛酮的確刺激THP-1細胞分泌galectin-3且經由礦物類皮質激素(鹽)受體途徑及PI3K/Akt所調控之細胞訊息傳遞途徑;其中NF-kB為其基因表現的重要轉錄分子。第六部份的研究是從基礎的細胞研究探討皮質醛酮是否刺激巨噬細胞分泌IL-6及其作用之機轉;研究中發現皮質醛酮的確刺激THP-1細胞分泌IL-6,而皮質醛酮誘發IL-6的表現是經由礦物類皮質激素(鹽)受體途徑,其與PI3K/Act及p38所調控之細胞訊息傳遞途徑有關;NF-kB及NF-IL-6是調控的重要轉錄分子。在第七部份的研究發現單側皮質醛酮素瘤患者較原發性高血壓患者有著較高的IL-6,但galectin-3兩組並無顯著差別;術後一年的追蹤,IL-6有明顯的下降,但galectin-3沒有變化。 而高血壓本身即為心臟血管疾病的一個十分重要的因子,而原發性皮質醛酮症是一個有機會可以治癒的常見高血壓疾病,它的重要性與日俱增,希望能藉由這些研究,讓大家更了解原發性皮質醛酮症及其對心血管系統的影響。 | zh_TW |
dc.description.abstract | Primary aldosteronism (PA) is a curable and common hypertensive disease, and is characterized by an inappropriate production of aldosterone. PA, the prevalence of which is around 5-10% of patients with hypertension, consists of two subtypes: aldosterone-producing adenoma (APA) and idiopathic hyperaldosteronism (IHA).
Patients with PA have been shown to have a higher prevalence of cardiovascular events and atrial fibrillation than patients with essential hypertension (EH), which are independent of blood pressure effects. In addition, patients with PA have a more prominent left ventricular (LV) mass, and a higher degree of LV diastolic function impairment and myocardial fibrosis than those with EH. In recent studies, macrophage-mediated low grade inflammation has been shown to play an important role in aldosterone-inducing cardiac fibrosis. However, the mediators of this process are still unclear. In order to investigate the change of cardiac structure and texture in PA patients and their relation to macrophage, we designed a series of studies. In the part, we found that serum potassium level was negatively associated with LV mass index (LVMI) in PA patients. Compared with patients with EH, PA patients had a greater impairment of cardiac diastolic function, which was independent of serum potassium level. In the second part, we found that LV hypertrophy in PA patients could be significantly reversed by adrenalectomy. Pre-operative LVMI and change of systolic blood pressure were associated with the degree of LVMI decrease. In the third and fourth part, we found that adrenalectomy reversed not only LV geometry but also altered myocardial texture in patients with unilateral hyperaldosteronism. This suggests that increases in collagen content in the myocardium of patients with unilateral hyperaldosteronism might be reversed by adrenalectomy. In the fifth part, we investigated whether aldosterone induced macrophage to secret galectin-3 and its mechanisms. We found that aldosterone induced the THP-1 cell to secret galectin-3 via mineralocorticoid receptors. The induced secretion occurred through the PI3K/Akt pathway, and NF-kB was an important transcriptional factor in this pathway. In the sixth part, we investigated whether aldosterone induced macrophage to secret IL-6 and its mechanisms. We found that aldosterone induced the THP-1 cell to secret IL-6 via mineralocorticoid receptors. The induced secretion was achieved through the PI3K/Akt and p38 pathway, and NF-kB and NF-IL-6 were important transcriptional factors in this pathway. In the seventh part, we found that patients with APA had higher plasma IL-6 levels than EH patients’ and the increased plasma IL-6 concentration decreased significantly one year after adrenalectomy in the APA patients. However, plasma galectin-3 levels were comparable in both groups, and there was also no change one year after adrenalectomy in the APA patients. As hypertension is an important risk factor of cardiovascular disease, and as PA is a curable and common hypertensive disease, the issues of PA are becoming increasingly important. It is hoped that these studies will promote a greater understanding of PA and its effect on the cardiovascular system. Key words: primary aldosteronism; aldosterone; left ventricular hypertrophy; cardiac fibrosis; IL-6; galectin-3 | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T00:36:08Z (GMT). No. of bitstreams: 1 ntu-100-D96421007-1.pdf: 1643012 bytes, checksum: 7a51d51b89ffcf04e3db34e705360342 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 口試委員會審定書……………………………………………………………………...2
誌謝…………………………………………………………………………………..…3 中文摘要………………………………………………………………………………4-5 英文摘要………………………………………………………………………………6-7 博士論文內容 1.緒論…………………………………………………………………………11-34 2.研究方法與材料……………………………………………………………….....35-47 3.結果…………………………………………………………………………….....48-57 4.討論…………………………………………………………………………….....58-78 5.展望…………………………………………………………………………….....79-88 6. 論文英文簡述………………………………. .………………………..………89-100 參考文獻………………………………. .……………………………….……. 101-115 表一--表二十四…………………………………………………………..…….. 116-146 圖一--圖十四……………………………………………………………….……147-160 圖註………………………………………………………………………………161-162 圖目錄 圖一…………………………………………………………………………..……….147 圖二…………………………………………………………………………..……….148 圖三…………………………………………………………………………..……….149 圖四…………………………………………………………………………..……….150 圖五…………………………………………………………………………..……….151 圖六…………………………………………………………………………..……….152 圖七…………………………………………………………………………..……….153 圖八…………………………………………………………………………..……….154 圖九…………………………………………………………………………..……….155 圖十…………………………………………………………………………..……….156 圖十一………………………………………………………………………..……….157 圖十二………………………………………………………………………..……….158 圖十三………………………………………………………………………..……….159 圖十四………………………………………………………………………..……….160 表目錄 表一…………………………………………………………………………..… 116-117 表二…………………………………………………………………………..… 118-119 表三…………………………………………………………………………..……….120 表四…………………………………………………………………………..……….121 表五…………………………………………………………………………..……….122 表六…………………………………………………………………………..……….123 表七…………………………………………………………………………..……….124 表八…………………………………………………………………………..…..125-126 表九…………………………………………………………………………..…..127-128 表十…………………………………………………………………………..……….129 表十一………………………………………………………………………..…..130-131 表十二………………………………………………………………………..……….132 表十三………………………………………………………………………..……….133 表十四………………………………………………………………………..……….134 表十五 ……………………………………………………………………..……….135 表十六………………………………………………………………………..…..136-137 表十七………………………………………………………………………..……….138 表十八………………………………………………………………………..……….139 表十九………………………………………………………………………..……….140 表二十………………………………………………………………………..……….141 表二十一……………………………………………………………………..……….142 表二十二……………………………………………………………………..…..143-144 表二十三……………………………………………………………………..……….145 表二十四……………………………………………………………………..……….146 | |
dc.language.iso | zh-TW | |
dc.title | 原發性皮質醛酮症患者的心臟結構重塑之研究 | zh_TW |
dc.title | Remodeling of cardiac structure in patients with primary aldosteronism. | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 楊偉勛,蘇銘嘉,褚柏顯,蔡有光 | |
dc.subject.keyword | 原發性皮質醛酮症,皮質醛酮,左心室肥大,心肌纖維化,IL-6,galectin-3, | zh_TW |
dc.subject.keyword | primary aldosteronism,aldosterone,left ventricular hypertrophy,cardiac fibrosis,IL-6,galectin-3, | en |
dc.relation.page | 162 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2012-02-03 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 1.6 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。